Nnz-2566    (DrugBank: -)

2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
156レット症候群2
206脆弱X症候群1

156. レット症候群 [臨床試験数:36,薬物数:49(DrugBank:19),標的遺伝子数:77,標的パスウェイ数:112
Searched query = "Rett syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 36 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02715115March 201621/2/2016A Safety Study of NNZ-2566 in Pediatric Rett SyndromeA Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of the Safety and Pharmacokinetics of Oral NNZ-2566 in Pediatric Rett SyndromeRett SyndromeDrug: NNZ-2566;Drug: PlaceboNeuren Pharmaceuticals Limitedrettsyndrome.orgCompleted5 Years15 YearsFemale82Phase 2United States
2NCT01703533March 20134/10/2012A Safety Study of NNZ-2566 in Patients With Rett SyndromeA Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation Study of NNZ-2566 in Rett SyndromeRett SyndromeDrug: NNZ-2566;Drug: PlaceboNeuren Pharmaceuticals LimitedBaylor College of Medicine;International Rett Syndrome FoundationCompleted16 Years45 YearsFemale67Phase 2United States

206. 脆弱X症候群 [臨床試験数:98,薬物数:73(DrugBank:27),標的遺伝子数:46,標的パスウェイ数:57
Searched query = "Fragile X syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 98 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01894958January 20143/7/2013A Safety Study of NNZ-2566 in Patients With Fragile X SyndromeA Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study of NNZ-2566 in Fragile X SyndromeFragile X SyndromeDrug: NNZ-2566;Drug: PlaceboNeuren Pharmaceuticals LimitedNULLCompleted12 Years45 YearsMale72Phase 2United States